参考文献/References:
[1] Medical Masterclass contributors,Firth J. Cardiology:hypertrophic?cardiomyopathy[J].Clin Med(Lond),2019,19(1):61-63.
[2] 邹玉宝,宋雷. 中国成人肥厚型心肌病诊断与治疗指南解读[J]. 中国循环杂志,2018,33(S2):68-73.
[3] Camm CF,Camm AJ. Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy[J]. Arrhythm Electrophysiol Rev,2017,6(2):63-68.
[4] 王皎. 室性期前收缩性心肌病诊疗进展[J]. 心血管病学进展,2020,41(6):563-566.
[5] Butt JH,Olesen JB,Havers-Borgersen E,et al. Risk of thromboembolism associated with atrial fibrillation following noncardiac surgery[J]. J Am Coll Cardiol,2018,72(17):2027-2036.
[6] Cao?ZJ,Guo?XG,Sun?Q,et al. Pulmonary vein isolation implemented by second-generation cryoballoon for treating hypertrophic cardiomyopathy patients with symptomatic atrial fibrillation:a case-control study[J]. J Geriatr Cardiol,2020,17(8):476-485.
[7] Sivalokanathan?S,Zghaib?T,Greenland?GV,et al. Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging[J]. JACC Clin Electrophysiol,2019,5(3):364-375.
[8] Rowin?EJ,Hausvater?A,Link?MS,et al . Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy[J]. Circulation,2017,136(25):2420-2436.
[9] Pavlou M,Guttmann OP,OMahony C,et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy[J]. Heart,2017,103(9):672-678.
[10]Cinar?T,Hayiro?lu?M?,?i?ek?V,et al. Predictors of left atrial thrombus in acute ischemic stroke patients without atrial fibrillation:a single-center cross-sectional study[J]. Rev Assoc Med Bras(1992),2020,66(10):1437-1443.
[11]Kong?Q,Shi?L,Yu?R,et al. Biatrial enlargement as a predictor for reablation of atrial fibrillation[J]. Int J Med Sci,2020,17(18):3031-3038.
[12]MacIntyre C,Lakdawala NK. Management of atrial fibrillation in hypertrophic cardiomyopathy[J]. Circulation,2016,133(19):1901-1905.
[13]邹玉宝,宋雷. 2017中国成人肥厚型心肌病诊断与治疗指南精要解读[J]. 中国分子心脏病学杂志,2018,18(2):2396-2400.
[14]Kirchhof P,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J,2016,37(38):2893-2962.
[15]Tuluce K,Yakar TS,Kahya EN,et al. Predictors of future atrial fibrillation development in patients with hypertrophic cardiomyopathy:a prospective follow-up study[J]. Echocardiography,2016,33(3):379-385.
[16]府晓丹. 高血压病心房颤动患者血尿酸代谢异常及CYP11B2-344T＞C基因多态性研究[D]. 重庆:第三军医大学,2015.
[17]Wang?Y,Morishima?M,Li?D,et al. Binge alcohol exposure triggers atrial fibrillation through T-type cachannel upregulation via protein kinase C (PKC) / glycogen synthesis kinase 3β (GSK3β) / nuclear factor of activated T-cells (NFAT) signaling—An experimental account of holiday heart syndrome[J]. Circ J,2020,84(11):1931-1940.
[18]Debonnaire P,Joyce E,Hiemstra Y,et al. Left?atrial?size and function in?hypertrophic?cardiomyopathy?patients and risk of new-onset?atrial?fibrillation[J]. Circ Arrhythm Electrophysiol,2017,10(2):e004052.
[19]Tuluce K,Ozerkan F,Yakar TS,et al. Relationships between P wave dispersion,atrial electromechanical delay,left atrial remodeling,and NT-proBNP levels,in patients with hypertrophic cardiomyopathy[J]. Cardiol J,2015,22(1):94-100.
[20]Conte G,Luca A,Yazdani S,et al. Usefulness of P-wave duration and morphologic variability to identify patients prone to paroxysmal atrial fibrillation[J]. Am J Cardiol,2017,119(2):275-279.
[21]Berge T,Lyngbakken MN,Ihle-Hansen H,et al. Prevalence of atrial fibrillation and cardiovascular risk factors in a 63-65 years old general population cohort:the Akershus Cardiac Examination (ACE) 1950 Study[J]. BMJ Open,2018,8(7):e021704.
[22]Magnussen C,Niiranen TJ,Ojeda FM,et al. Sex differences and similarities in atrial fibrillation epidemiology,risk factors,and mortality in community cohorts:results from the biomarcare consortium (biomarker for cardiovascular risk assessment in Europe)[J]. Circulation,2017,136(17):1588-1597.
[23]Bening C,Mazalu EA,Yaqub J,et al. Atrial contractility and fibrotic biomarkers are associated with atrial fibrillation after elective coronary artery bypass grafting[J]. J Thorac Cardiovasc Surg,2020,159(2):515-523.
[24]Jain R,Osranek M,Jan MF,et al. Marked respiratory-related fluctuations in?left?ventricular?outflow?tractgradients in?hypertrophic?obstructive?cardiomyopathy:an observational study[J]. Eur Heart J Cardiovasc Imaging,2018,19(10):1126-1133.
[25]李璐,程赛楠,崔辰,等. 肥厚型心肌病类缺血样强化的MRI特征及临床价值[J]. 中华放射学杂志,2018,52(12):903-907.
[26]安硕研. 肥厚型心肌病的预后研究[D]. 北京:北京协和医学院,2018.
[27]Raman B,Ariga R,Spartera M,et al. Progression of?myocardial?fibrosis?in?hypertrophic?card iomyopathy:mechanisms and clinical implications[J]. Eur Heart J Cardiovasc Imaging,2019,20(2):157-167.
[28]Siontis?KC,Geske?JB,Ong?K,et al. Atrial fibrillation in hypertrophic cardiomyopathy:prevalen ce,clinical correlations,and mortality in a large high-risk population[J]. J Am Heart Assoc,2014,3(3):e001002.
[29]Lee SE,Park JK,Uhm JS,et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy[J]. Heart,2017,103(19):1496-1501.
[30]Guttmann OP,Pavlou M,OMahony C,et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)[J]. Eur J Heart Fail,2015,17(8):837-845.
[31]Kogut J,Popjes ED. Hypertrophic?cardiomyopathy?2020[J]. Curr Cardiol Rep,2020,22(11):154.
[32]Yalta K,Kaya C. Recurrent Takotsubo?cardiomyopathy:a puzzle yet to be solved[J]. Arq Bras Cardiol,2020,115(3):590-591.
[33]Patten M,Pecha S,Aydin A. Atrial fibrillation in hypertrophic cardiomyopathy:diagnosis and considerations for management[J]. J Atr Fibrillation,2018,10(5):1556-1556.
[34]Liu L,Li J,Zuo L,et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy[J]. J Am Coll Cardiol,2018,72(16):1898-1909.
[35]Fitzgerald P,Kusumoto F. The effects of septal myectomy and alcohol septal?ablation?for?hypertrophic cardiomyopathy?on the cardiac conduction system[J]. J Interv Card Electrophysiol,2018,52(3):403-408.
[36]Zhou Y,He W,Zhou Y,et al. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation:a systematic review and meta-analysis[J]. J Thromb Thrombolysis,2020,50(2):311-317.
[37]Jung H,Yang PS,Jang E,et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patie nts with atrial fibrillation with hypertrophic cardiomyopathy:a nationwide cohort study[J]. Chest,2019,155(2):354-363.
[38]Rujirachun P,Charoenngam N,Wattanachayakul P,et al. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy:a systematic review and meta-analysis[J]. Acta Cardiol,2019,26(1):1-8.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(4):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(4):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[4]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(4):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[5]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(4):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[6]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(4):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[7]王梓良 何一秀 林伟力 张再磊 褚银平.单纯左心耳干预预防心源性脑卒中的研究进展[J].心血管病学进展,2021,(11):1007.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
WANG ZiliangHE YixiuLIN WeiliZHANG ZaileiCHU Yinping.Prevention of Cardiogenic Stroke by Simple Intervention of Left Atrial Appendage[J].Advances in Cardiovascular Diseases,2021,(4):1007.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[8]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(4):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[9].LAmbreTM封堵器与新型口服抗凝药物预防心房颤动患者血栓栓塞事件的对照研究[J].心血管病学进展,2021,(11):1036.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
LI YahuiWANG XuewenHUANG Congxin.A Comparative Study of LAmbreTM Device and Direct Oral Anticoagulants in Preventing Thromboembolic Events in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(4):1036.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[10]李传伟,罗浩,曾春雨.肥厚型心肌病室间隔消减策略的研究进展[J].心血管病学进展,2022,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
LI Chuanwei,LUO Hao,ZENG Chunyu.Septal Reduction Therapy of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(4):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]